KYNTRA BIO, INC. (KYNB) stock intrinsic value fair value estimate & owner earnings analysis

Kyntra Bio (formerly FibroGen) is a small clinical-stage drug developer. In August 2025 it sold its China and international operations to AstraZeneca for $210.4 million and used part of the proceeds to repay its $75 million term loan. What remains is a U.S. company with three things: (1) FG-3246, an antibody-drug conjugate for advanced (metastatic castration-resistant) prostate cancer, licensed from Fortis Therapeutics and now in a Phase 2 dose-optimization study with an interim analysis expected in the fourth quarter of 2026; (2) U.S., Canadian and Mexican rights to roxadustat, for which it plans a new Phase 3 trial in lower-risk myelodysplastic syndrome in patients with heavy transfusion needs, targeted to start in the fourth quarter of 2026, either alone or with a partner; and (3) a small revenue stream from supplying roxadustat to Astellas for Japan and Europe, about $5 to $6 million a year. The business does not earn money; it spends it. Measured as cash generated for owners after stock-based pay, it lost about $43 million in 2025 and is running at a loss of roughly $55 to $60 million a year in 2026 as the FG-3246 trial and roxadustat trial preparation ramp up. Its history before 2025 describes a much larger company with China sales and a since-abandoned lead drug, so it is not used as a guide. The cash cushion at June 30, 2026 was $95.3 million in cash and investments, which management says lasts into 2028. The most important fact in this analysis is the company's royalty-financing agreement with NovaQuest. In 2022 the company received $50 million in exchange for a share of its Astellas revenue, but the contract also requires guaranteed catch-up payments: total payments must reach $62.5 million by the end of 2028 (any shortfall due by March 1, 2029) and $125 million by the end of 2030 (shortfall due by March 1, 2031). The company has paid only about $8 million so far, so roughly $117 million is still owed over the next four and a half years. The balance sheet shows this obligation at about $70 million only because it is discounted at roughly 15% a year; in plain cash terms it is much larger. The company can settle it early for about $92 million if it pays before the end of 2028, but cannot do so from today's cash while also funding its trials. In present-value terms the obligation is worth about $81 million if prepaid by 2028 and about $96 million if paid on the contractual schedule. Our previous estimate treated this obligation at its smaller book figure, which is the main reason the figures below are much lower than before. Other items: a Finnish subsidiary declared bankruptcy in April 2026, which removed about $19.6 million of Finnish government loans from the books; those loans were never repayable by the parent, so this does not change our estimate. The final $4 million AstraZeneca holdback was received in June 2026. About $21.5 million of preferred interests in Fortis appear on the balance sheet; they matter only if the company exercises its option to buy Fortis for $80 million by December 31, 2027, which it cannot fund today without a partner. We counted stock-based pay as a real cost and added back non-cash accounting interest on the NovaQuest liability, valuing the actual cash payments to NovaQuest instead. Bear case (about a 1-in-10 outcome): the FG-3246 interim data disappoint, the company starts the roxadustat Phase 3 on its own as planned, and it spends essentially all of its cash by early 2028, as happened in 2024 when its former lead drug pamrevlumab failed two Phase 3 trials. The 2022 to 2023 biotech funding drought shows that raising money after a failure is very difficult. Astellas supply revenue halves (it already swung negative in the second quarter of 2026 on a $2.9 million downward revision). In this case the business, including its cash, is worth about negative $5 million after restructuring costs, while it owes NovaQuest about $96 million, leaving the company owing roughly $100 million more than it is worth, about negative $24.77 per share. In practice shareholders would likely be wiped out in a restructuring. Base case (the middle outcome): spending continues at the current pace through the interim readout and into mid-2027, and with no partnership signed the company then cuts back sharply, as it did after the 2024 failures, becoming a small holder of the Astellas revenue stream. We give no value to a future licensing deal because none is signed and the drug's Phase 2 results are not yet known. The business, including its remaining cash and the fading Astellas revenue, is worth about $34 million; it owes NovaQuest about $96 million on the scheduled payments, since it could not afford to prepay. The company appears to owe about $62 million more than it is worth, about negative $15.28 per share. Bull case (about a 1-in-10 upside outcome): the FG-3246 interim data are clearly positive, and by mid-2027 a larger drug company licenses it, pays for the $80 million Fortis option and future development, and pays Kyntra about $75 million upfront; roxadustat's Phase 3 is also partnered. The 2023 Fortis option terms ($80 million plus up to $200 million in approval milestones, set before Phase 2) are the evidence for the scale of value such a deal could carry. Kyntra then prepays NovaQuest by 2028 for about $92 million and runs a lean operation. The business is worth about $209 million and owes about $81 million, leaving about $31.68 per share. How we set the margin-of-safety price: we are confident about the level of spending and about the NovaQuest obligation, because both are set by contracts and recent filings. We are not confident about anything that would create value, because it all depends on one Phase 2 readout and on a partner showing up. The worst plausible outcome is a total loss: the company's structure (a fixed $117 million obligation coming due in 2029 and 2031, no product sales of its own, two programs that both need partners) would not survive a clinical failure without wiping out shareholders. If we are wrong about the data, the shares are worth nothing; if we are wrong about partnering, the same; only both going right produces value. The company pays nothing during the holding period. On today's facts there is no margin-of-safety price, because both the median and the downside outcomes leave nothing for shareholders. If a partnership is signed that brings at least $50 million of upfront cash and takes over development costs, the NovaQuest problem becomes manageable and the shares would be worth roughly $15 in a middle outcome and a few dollars in a poor one; the margin-of-safety price would then be $7, a price from which the cases would imply a reasonable chance of a 20% annual return over an assumed holding period of about three years, with a cash-backed floor. What would make this analysis wrong: a renegotiation or early settlement of the NovaQuest agreement at a large discount, strongly positive FG-3246 data that attract an acquisition of the whole company, or a much faster spending cut than management has indicated.